Gordon Cohen
- Surgery
- Oncology
- Pulmonary and Respiratory Medicine
- Hepatology top 10%
- Pathology and Forensic Medicine
- Co-authors
- Nana RokutandaDo‐Youn OhArndt VogelMohamed BouattourHoward A. BurrisTakuji OkusakaMyung Ah LeeJin Won Kim
- Topics
- Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers)Pancreatic and Hepatic Oncology Research (4 papers)Gallbladder and Bile Duct Disorders (3 papers)
- Cited by
- HepatologyOncologySurgery
- Partner nations
- United StatesJapanSouth Korea
In The Last Decade
Gordon Cohen
9 papers receiving 363 citations
Hit Papers
Peers
Comparison fields: 5 of 33
- Surgery 240
- Oncology 228
- Pulmonary and Respiratory Medicine 110
- Hepatology 109
- Pathology and Forensic Medicine 75
Countries citing papers authored by Gordon Cohen
This map shows the geographic impact of Gordon Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Cohen more than expected).
Fields of papers citing papers by Gordon Cohen
This network shows the impact of papers produced by Gordon Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Cohen. The network helps show where Gordon Cohen may publish in the future.
Co-authorship network of co-authors of Gordon Cohen
This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Cohen. A scholar is included among the top collaborators of Gordon Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Cohen. Gordon Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trialbreakdown → | 51 |
| 2 | EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.breakdown → | 93 |
| 3 | 2 | |
| 4 | 13 | |
| 5 | 12 | |
| 6 | 12 | |
| 7 | A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.breakdown → | 159 |
| 8 | 15 | |
| 9 | 8 |
About Gordon Cohen
Gordon Cohen is a scholar working on Oncology, Hepatology and Pharmacy, having authored 9 papers that have together received 365 indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Gallbladder and Bile Duct Disorders (3 papers). The work is most often cited by research in Hepatology (109 citations), Oncology (228 citations) and Surgery (240 citations). Gordon Cohen has collaborated with scholars based in United States, Japan and South Korea. Frequent co-authors include Nana Rokutanda, Do‐Youn Oh, Arndt Vogel, Mohamed Bouattour, Howard A. Burris, Takuji Okusaka, Myung Ah Lee, Jin Won Kim, Aiwu Ruth He and Li‐Tzong Chen. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology and Quality of Life Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.